Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.

ABSTRACT: Although CAR T-cell therapy has demonstrated tremendous clinical efficacy especially in hematological malignancies, severe treatment-associated toxicities still compromise the widespread application of this innovative technology. Therefore, developing novel approaches to abrogate CAR T-cell-mediated side effects is of great relevance. Several promising strategies pursue the selective antibody-based depletion of adoptively transferred T cells via elimination markers. However, given the limited half-life and tissue penetration, dependence on the patients' immune system and on-target/off-side effects of proposed monoclonal antibodies, we sought to exploit αCAR-engineered T cells to efficiently eliminate CAR T cells. For comprehensive and specific recognition, a small peptide epitope (E-tag) w

SUBMITTER: Koristka S 

PROVIDER: S-EPMC6768917 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature